Adeola Shobo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3758344/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Aβ34 is a BACE1-derived degradation intermediate associated with amyloid clearance and Alzheimer's disease progression. Nature Communications, 2019, 10, 2240.	12.8	39
2	Visualization of Time-Dependent Distribution of Rifampicin in Rat Brain Using MALDI MSI and Quantitative LCMS/MS. Assay and Drug Development Technologies, 2015, 13, 277-284.	1.2	25
3	Neurodegenerative Disease-Related Proteins within the Epidermal Layer of the Human Skin. Journal of Alzheimer's Disease, 2019, 69, 463-478.	2.6	22
4	The amyloid-β degradation intermediate Aβ34 is pericyte-associated and reduced in brain capillaries of patients with Alzheimer's disease. Acta Neuropathologica Communications, 2019, 7, 194.	5.2	20
5	Labelâ€free distribution of antiâ€amyloid Dâ€AIP in Drosophila melanogaster : prevention of Aβ42â€induced toxicity without side effects in transgenic flies. Journal of Neurochemistry, 2019, 150, 74-87.	3.9	7
6	Insights into the Impact of Gold Nanoclusters Au ₁₀ SG ₁₀ on Human Microglia. ACS Chemical Neuroscience, 2022, 13, 464-476.	3.5	7
7	Biophysical characterization as a tool to predict amyloidogenic and toxic properties of amyloidâ€Î²42 peptides. FEBS Letters, 2022, 596, 1401-1411.	2.8	2
8	The amyloid-β1–42-oligomer interacting peptide D-AIP possesses favorable biostability, pharmacokinetics, and brain region distribution. Journal of Biological Chemistry, 2022, 298, 101483.	3.4	1